Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no ...
HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but these celebrations were tempered by insurers’ reluctance to cover its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results